Mark E. Dudley
Impact in
- Immunology top 0.02%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Oncology top 0.01%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
Papers in
- Oncology 81
- CAR-T cell therapy research 78
- Cancer Immunotherapy and Biomarkers 11
- Immunology 70
- Immunotherapy and Immune Responses 56
- Immune Cell Function and Interaction 23
- T-cell and B-cell Immunology 14
- Co-authors
- Steven A. Rosenberg (85 shared papers)Nicholas P. Restifo (20 shared papers)John R. Wunderlich (35 shared papers)James C. Yang (20 shared papers)Richard A. Morgan (12 shared papers)Paul F. Robbins (23 shared papers)Richard M. Sherry (21 shared papers)James Chih‐Hsin Yang (11 shared papers)
- Journals
- Journal of Immunotherapy (16 papers)The Journal of Immunology (14 papers)Blood (10 papers)Clinical Cancer Research (10 papers)Human Gene Therapy (5 papers)
- Partner nations
- United StatesGermanyMalaysia
In The Last Decade
Mark E. Dudley
113 papers receiving 29.0k citations
Mark E. Dudley's Hit Papers
Peers
Comparison fields: 5 of 130
- Immunology 18.4k
- Oncology 22.1k
- Genetics 5.2k
- Molecular Biology 6.3k
- Biotechnology 741
Countries citing papers authored by Mark E. Dudley
This map shows the geographic impact of Mark E. Dudley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Dudley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Dudley more than expected).
Fields of papers citing papers by Mark E. Dudley
This network shows the impact of papers produced by Mark E. Dudley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Dudley. The network helps show where Mark E. Dudley may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark E. Dudley, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 114 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes Hit paper breakdown → | 2002 | 2175 |
| 2 | Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes Hit paper breakdown → | 2006 | 1977 |
| 3 | Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2 Hit paper breakdown → | 2010 | 1975 |
| 4 | Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy Hit paper breakdown → | 2011 | 1618 |
| 5 | Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma Hit paper breakdown → | 1998 | 1478 |
| 6 | Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired Hit paper breakdown → | 2009 | 1401 |
| 7 | Adoptive immunotherapy for cancer: harnessing the T cell response Hit paper breakdown → | 2012 | 1309 |
| 8 | Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer Hit paper breakdown → | 2014 | 1293 |
| 9 | Adoptive cell transfer: a clinical path to effective cancer immunotherapy Hit paper breakdown → | 2008 | 1264 |
| 10 | B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells Hit paper breakdown → | 2011 | 1140 |
| 11 | Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 Hit paper breakdown → | 2010 | 1045 |
| 12 | Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens Hit paper breakdown → | 2008 | 1022 |
| 13 | T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis Hit paper breakdown → | 2010 | 798 |
| 14 | PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors Hit paper breakdown → | 2014 | 783 |
| 15 | A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response Hit paper breakdown → | 2014 | 598 |
| 16 | Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients Hit paper breakdown → | 2003 | 539 |
| 17 | Adoptive-cell-transfer therapy for the treatment of patients with cancer Hit paper breakdown → | 2003 | 534 |
| 18 | Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells Hit paper breakdown → | 2015 | 514 |
| 19 | 2009 | 461 | |
| 20 | 2004 | 376 |
About Mark E. Dudley
Mark E. Dudley is a scholar working on Oncology, Immunology, Genetics, Molecular Biology and Biotechnology, having authored 114 papers that have together received 29.6k indexed citations. Recurring topics across this work include CAR-T cell therapy research (78 papers), Immunotherapy and Immune Responses (56 papers), Virus-based gene therapy research (29 papers), Immune Cell Function and Interaction (23 papers), T-cell and B-cell Immunology (14 papers), Cancer Immunotherapy and Biomarkers (11 papers), vaccines and immunoinformatics approaches (7 papers) and CRISPR and Genetic Engineering (6 papers). The work is most often cited by research in Immunology (18.4k citations), Oncology (22.1k citations), Genetics (5.2k citations), Molecular Biology (6.3k citations) and Biotechnology (741 citations). Mark E. Dudley has collaborated with scholars based in United States, Germany and Malaysia. Frequent co-authors include Steven A. Rosenberg, Nicholas P. Restifo, John R. Wunderlich, James C. Yang, Richard A. Morgan, Paul F. Robbins, Richard M. Sherry, James Chih‐Hsin Yang, Donald E. White and Carolyn M. Laurençot. Their work appears in journals such as Journal of Immunotherapy, The Journal of Immunology, Blood, Clinical Cancer Research and Human Gene Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.